ArticleJournal of translational medicine2026
M2-like GAMs secreting CSTA drive glioblastoma progression via the ITGB4-TGFB1 feedback axis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTumor microenvironment (TME) remodeling is a hallmark of gliomas. Glioma-associated macrophage/microglia (GAMs), the most abundant cellular component in the glioma TME, play critical roles in driving glioma progression, though the specific GAM subsets and their regulatory mechanisms remain unclear. This study investigates glioma-GAM crosstalk, identifies GAM subsets that regulate glioblastoma (GBM) progression, clarifies the role and mechanism of CSTA, and explores its clinical relevance.
methodsWith bulk RNA-seq and scRNA-seq datasets, a CSTA⁺ M2-like GAM subset was identified. In vitro and in vivo models confirmed CSTA’s pro-oncogenic effect on GBM. In vitro studies explored the mechanisms of CSTA upregulation in M2-like GAMs and its role in advancing GBM progression. Mass spectrometry and molecular docking predicted and validated CSTA’s interacting protein targets. Clinical cohort analyses evaluated the relationship between CSTA and glioma grades.
resultsM2-like polarization activates p44/p42 (ERK1/2) phosphorylation in the MAPK pathway, upregulating the c-JUN/c-FOS (AP-1) transcription complex and promoting CSTA expression in GAMs. CSTA binds to ITGB4 at glutamate residue 88, activating downstream NF-κB and MAPK signaling in GBM cells to drive progression. Moreover, the CSTA-ITGB4 axis induces GBM cells to secrete TGFB1, which recruits M2-like GAMs and exacerbates TME immunosuppression. Additionally, CSTA levels in peripheral blood and cerebrospinal fluid (CSF) correlate positively with glioma grade.
conclusionsCSTA⁺ M2-like GAMs promote GBM malignancy via the CSTA-ITGB4 axis, activating downstream NF-κB and MAPK signaling and forming a TGFB1-mediated positive feedback loop. Notably, CSTA correlates with glioma grades and has independent prognostic and potential therapeutic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.